• <strike id="xmwty"><table id="xmwty"></table></strike>
    <progress id="xmwty"></progress>

      <b id="xmwty"></b>

      ×

      Tonghua Dongbao announces NMPA acceptance of its clinical trial application for oral small-molecule GLP-1 receptor agonist (THDBH110 Capsules)

      Date:2023-08-22
      Author:東寶
      Views:1

      Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") received a notice of acceptance (No. CXHL2300887) from the Center for Drug Evaluation of the National Medical Products Administration (NMPA) for the clinical trial of the oral small-molecule GLP-1 receptor agonist (THDBH110 Capsules).

       

      The glucagon-like peptide 1 (GLP-1) receptor is a prominent target for treating type 2 diabetes and obesity. GLP-1 receptor agonists have significant therapeutic potential and market reach. Accordingly, the Company is advancing the development of various GLP-1 receptor agonists, including liraglutide injections, dual GLP-1/GIP receptor agonists, and oral small-molecule GLP-1 receptor agonists.

       

      About THDBH110 Capsules

      GLP-1 receptor agonists on the market are injections, made up of large molecules or polypeptides, with less-than-satisfactory medication adherence. The Company's THDBH110 is an oral, small-molecule alternative. Preclinical results show that the THDBH110 capsule is highly bioavailable and effective in reducing glucose levels and weight. This product not only provides a new treatment option for lowering glucose, reducing weight, and protecting cardiovascular system for type 2 diabetes and obesity patients, but also improves medication convenience and adherence. To date, no oral small-molecule GLP-1 receptor agonists have been approved globally.

       

      As an effective hypoglycemic agent, GLP-1 receptor agonists have a promising market outlook. China ranks first globally in the number of diabetes patients, with around 140 million adult patients as per 2021 data from the International Diabetes Federation (IDF). The demand for GLP-1 receptor agonist drugs is surging. According to data from Menet.com, in 2022, the sales of GLP-1 receptor agonist drugs in Chinese public medical institutions and urban brick-and-mortar pharmacies, reached nearly RMB 6 billion, a year-on-year growth of over 100%.

       

      GLP-1 receptor agonists, with their notable weight loss benefits and controllable side effects, are a primary recommendation in international obesity treatment guidelines. Overweight and obesity are associated with severe health risks, such as cardiovascular diseases, diabetes, and musculoskeletal disorders. As China's guidelines for treating obesity gradually align with international standards, the potential for GLP-1 receptor agonists in weight loss treatments is immense.

       

      The clinical trial acceptance of THDBH110 marks a significant step for the Company in the R&D of GLP-1 receptor agonists. We will advance our R&D swiftly and efficiently to provide patients with more effective and safe GLP-1 receptor agonist options.


      0 国产在线看片av免费,91中文字幕 国产,国产丝袜脚足j在线视频播放,黄视频在线观看无码免费
    1. <strike id="xmwty"><table id="xmwty"></table></strike>
      <progress id="xmwty"></progress>

        <b id="xmwty"></b>

        国产高清视频| 亚洲国产天堂91久久| 精品无码三级婷婷| 一本到无码在线视频观看| 免费在线观看a国产种片| av无码国产在线看岛国| 国产欧美日韩第一章午夜在线| 欧美精品国产免费无| 一级做片免费观看久久| 日韩精品无码人成视频手机| 亚洲国产综合精品中久| 91亚洲国产第一精品| 国产精品亚洲香蕉第五区| 一级特黄毛片| 一级欧美精片一区二区三区| 动漫精品无码精品国产一区| 6摸国产精品无码一区二区三区视频| 在线亚洲欧美日韩精品专区| 国产呦精品一区二区三区视频| 蜜臀色欲91Av在线一区二区| 国产精品扒开腿做爽爽爽的事情| 免费国产a国产片高清下载| 免费无码专区毛片高潮喷水在线| 亚洲精品AⅤ在线观看| yellow精品在线观看免费观看视频| 日本久久久亚洲中文字幕| 日韩无砖专区中文字幕| 人妻免费福利碰碰碰| 亚洲欧美视频在线观看|